Stockreport

Imunon targets ~80 OVATION 3 patients in the next 12 months as cash runway extends into H2 2026 [Seeking Alpha]

Imunon, Inc.  (IMNN) 
PDF Stacy Lindborg (President, CEO & Director) said the company entered 2026 “with strong momentum” and highlighted a new final overall survival update from OVATION 2: “the [Read more]